Inside the research
Embecta Corp.
EMBC Research profile · latest available data
Price overview
$5.90
▲ +0.28 (+5.0%)
| 52w hi | $14.24 |
|---|---|
| 52w lo | $2.89 |
| Vol | 791.80K |
| As of | 25 Sep 2026 |
The Verdict
Our score -0.23
| Short | -0.36 |
|---|---|
| Medium | -0.16 |
| Long | -0.12 |
computed 2026-09-27
Key fundamentals
Embecta Corp.
Healthcare · Medical Instruments & Supplies
| Market cap | $334.29M |
|---|---|
| Enterprise value | $1.62B |
| Trailing P/E | 4.01x |
| Forward P/E | 3.35x |
| EV / EBITDA | 5.76x |
| P / S (ttm) | 0.33x |
| Profit margin | 8.6% |
| Revenue growth | -8.1% |
| Earnings growth | -53.7% |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.13 | |
| Sector | +0.08 | |
| Technical | -0.26 | |
| Earnings | +0.00 | |
| Sentiment | +0.00 |
macro × 1.00 · 2026-09-27
Business overview
Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. It primarily sells its products to wholesalers and distributors. The company was formerly known as Berra Newco, Inc. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.
Risk Metrics
| Beta vs SPX | 0.87 |
|---|---|
| Corr SPX | 0.19 |
| Annual vol | 72.4% |
| Annual ret | -17.2% |
| Sharpe | -0.24 |
| Max DD | -86.1% |
Window: 504 trading days (504 obs)
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-08-07 | Earnings Release, Exhibits | read |
| 2026-05-15 | Acquisition / Disposition, Reg FD Disclosure… | read |
| 2026-05-05 | Earnings Release, Exhibits | read |
| 2026-03-20 | Material Agreement, Reg FD Disclosure… | read |
| 2026-02-13 | Shareholder Vote | read |
| 2026-02-05 | Earnings Release, Exhibits | read |
| 2025-11-25 | Earnings Release, Exhibits | read |
| 2025-11-17 | Officer / Director Change, Exhibits | read |
| 2025-08-08 | Earnings Release, Exhibits | read |
| 2025-05-22 | Reg FD Disclosure, Exhibits | read |
| 2025-05-09 | Earnings Release, Exhibits | read |
| 2025-02-14 | Shareholder Vote | read |
Flow & Concentration
| Insider 180d net | $0 |
|---|---|
| Insider buys / sells | 0 / 0 |
| Insider bias | Neutral |
| 13F holders | 7 |
| Top-5 share | 97.7% |
| HHI | 2,194 (moderate) |
Top Holders
| Holder | Value | Shares |
|---|---|---|
| State Street Corp | $5.25M | 1.61M |
| AQR Capital Management | $3.17M | 976.59K |
| Millennium Management | $3.08M | 945.97K |
| Capital Research / Capital World | $2.70M | 829.10K |
| Citadel Advisors | $1.52M | 465.79K |
| Fidelity / FMR LLC | $371.49K | 113.95K |
| T. Rowe Price Group | $315 | 96.39K |
As of 2026-06-30
SEC Filings
The Long Run
FY 2022–2025 · 4 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $1.08B | -2.5% | |
| Gross profit | $676.80M | -3.9% | |
| Operating income | $221.50M | -10.6% | |
| Net income | $95.40M | -24.7% | |
| Cash from ops | $67.70M | -48.6% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $5.67 | $5.93 | $5.63 | $5.90 | 791.80K |
| Sep 24 | $5.63 | $5.72 | $5.45 | $5.62 | 925.90K |
| Sep 23 | $5.59 | $5.66 | $5.54 | $5.58 | 692.10K |
| Sep 22 | $5.38 | $5.61 | $5.38 | $5.59 | 681.20K |
| Sep 21 | $5.24 | $5.34 | $5.13 | $5.30 | 930.30K |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →